News | January 29, 2013

New Test May Reduce Time in Diagnosing Heart Attacks, Assist in Determining Risk for Future MI

Abbot Vascualr Architect Stat Blood Testing Point-of-Care Testing

January 29, 2013 — An estimated 17 million people throughout the world die annually of cardiovascular diseases, specifically heart attacks or strokes.[1] Time is a critical factor in diagnosing and treating people who may be having a potential heart attack. To aid physicians in detecting heart attacks sooner, Abbott announced CE marking (Conformite Europeenne) for the Architect Stat High Sensitive Troponin-I Assay.

Diagnosing Potential Heart Attacks

The preferred biomarker used to identify suspected heart attacks is cardiac troponin, a protein found in the heart muscle, because it can detect injury to the heart.[2] Many patients who visit the emergency room with chest pain complaints and a suspected heart attack currently have blood samples drawn for troponin tests upon admission, after 6 hours, and then potentially 12 hours later before a diagnosis may be made.[3] For patients who are having a heart attack, the length of time to diagnosis is a crucial factor because the heart muscle cells start to die after the heart stops receiving blood, and eventually, almost all the affected parts of the heart could be irreversibly damaged.  

Abbott's new Architect Stat High Sensitive Troponin-I Assay can measure very low levels of the protein, which allows doctors to evaluate whether or not patients are having a heart attack within two to four hours.[4] This faster evaluation could allow doctors to reduce the time to diagnosis and treatment by several hours when compared to standard troponin tests.

"The advantage of high sensitive troponin tests compared to current tests is that clinicians may now more precisely confirm or exclude a heart attack much sooner and with higher accuracy compared to contemporary tests," said Professor Stefan Blankenberg, director of cardiology at the University Heart Center of Hamburg, Germany. "This is important information for patient care because we can pursue treatment if needed or avoid invasive therapy and discharge a patient earlier."

Determining Risk for Future Cardiovascular Events

Another concern for patients who have experienced symptoms of a heart attack or who suffered from an actual attack is that they are at a higher risk for experiencing a second cardiac event or heart attack within a few weeks or months. Abbott's High Sensitive Troponin-I Assay also enables doctors to determine if patients are at risk to suffer from cardiovascular events 30 days and 90 days later.

"The sooner a patient can be diagnosed with a cardiac event, the faster a patient can get the care he or she needs," said Brian Blaser, executive vice president, Diagnostics Products, Abbott. "Abbott's new high sensitive troponin test is an innovative tool to help physicians diagnose more quickly, potentially improving the way heart attacks are diagnosed for patients around the world."

The new assay runs on Abbott's fully-automated Achitect family of analyzers and is available in CE marked and non-regulated countries, pending country registration.

Intended Use

The Architect Stat High Sensitive Troponin-I assay is a chemiluminescent microparticle immunoassay (CMIA) for the quantitative determination of cardiac troponin I (cTnI) in human plasma and serum on the Architect i System with STAT protocol capability. The cTnI values are used as an aid in the diagnosis of myocardial infarction (MI) and to aid in the assessment of 30-day and 90-day prognosis relative to all-cause mortality and major adverse cardiac events (MACE) consisting of myocardial infarction, revascularization, and cardiac death in patients who present with symptoms suggestive of acute coronary syndrome (ACS).

For more information: www.abbott.com

 

References:

1. Cardiovascular Diseases Fact Sheet No 317. World Health Organization, September 2012. Web site:www.who.int/mediacentre/factsheets/fs317.

2. Thygesen K, Alpert JS, Jaffe AS et al. Third universal definition of myocardial infarction. European Heart Journal. 2012; 33:2551-2567.

3. Thygesen K, Alpert JS, White HD et al.  Universal definition of myocardial infarction. European Heart Journal. 2007; 28:2525-38.

4. Abbott ARCHITECT STAT High Sensitive Troponin-I Product Insert (PI), January 2013.

5. Cardiovascular Diseases Fact Sheet No 317. World Health Organization, September 2012. Web site:www.who.int/mediacentre/factsheets/fs317.

Related Content

Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing| September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Siemens Healthineers to Acquire Epocal from Alere
News | Point of Care Testing| July 26, 2017
Siemens Healthineers has entered into a definitive agreement to acquire Epocal Inc., a subsidiary of Alere Inc. Epocal...
Alere point of care POC testing for INR
News | Point of Care Testing| July 17, 2017 | Dave Fornell
July 17, 2017 — Despite issues with point-of-care INR testing company Alere Inc., Abbott announced this week it is on
Sponsored Content | Videos | Cardiovascular Ultrasound| June 07, 2017
Chi-Ming Chow, M.D., MSc, FRCPC, FACC, FASE, attending staff cardiologist, St.
Siemens Xprecia Stride anticoagulation, coagulation PT/INR or INR testing at the point of care (POC)

Point-of-care coagulation PT/INR testing with handheld devices can help improve outcomes with more convenient and frequent measurements to keep patients within the therapeutic range of anticoagulant agents.

Feature | Point of Care Testing| May 05, 2017 | Nicholas C. Vanderslice, Ph.D., and Arnol S. Rios
Point-of-care (POC) coagulation analyzers that measure prothrombin time/international normalized ratio (PT/INR) on fi
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing| May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing| April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing| April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
PTS Diagnostics, FDA 510k clearance, extended HDL range, lipid panel test strips
News | Blood Testing| April 05, 2017
PTS Diagnostics announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded top range for...
highly sensitive troponin testing
News | Cardiac Diagnostics| March 21, 2017
March 21, 2017 — A blood test for a protein called high-sensitivity troponin T, which is released into the bloodstrea
Overlay Init